Aeglea adopts Spyre rebrand with focus on long-acting IBD therapies
27 Nov 2023
Executive ChangePhase 3AcquisitionPhase 2
Aeglea BioTherapeutics on Monday announced it is taking on the name of Spyre Therapeutics, following its acquisition of the privately-held company in June. It also appointed Cameron Turtle as chief executive, and made new additions to its management team to advance a pipeline of long-acting antibody product candidates for inflammatory bowel disease (IBD).
"We look forward to initiating clinical studies of our lead programmes against α4β7 and TL1A next year, followed shortly thereafter by our IL-23 programme. These programmes are expected to be the basis of combination therapy studies to follow," said Turtle. Prior to this new appointment as CEO, Turtle had been the chief operating officer at Spyre and has also served as the chief strategy officer of BridgeBio Pharma and chief business officer of Eidos Therapeutics.
Crowding TL1A field
Roche recently doubled down on TL1A last month when it put up $7.1 billion upfront to gain rights to anti-TL1A antibody RVT-3101 in the US and Japan via the acquisition of Telavant (for more, see Roche’s $7.1-billion deal to acquire Televant represents the company jumping on board with what could now be considered a TL1A trend). Other key players in the field include Merck & Co. and Sanofi.
Prior to its acquisition by Aeglea in June, the lead programmes of Spyre – a spinout of Paragon Therapeutics – SPY001 and SPY002, that are potentially best-in-class antibodies targeting a4b7 and TL1A, respectively. SPY001 is currently progressing through investigational new drug (IND)-enabling studies and is expected to enter first-in-human studies in the first half of 2024, with data due by the end of that year to validate a potential every-other-month or quarterly (Q8-Q12W) subcutaneous dosing profile.
Meanwhile, Spyre expects to move SPY002 into the clinic in the second half of 2024, with healthy volunteer data due in the first half of 2025. "TL1A has emerged as one of the most promising targets in IBD and broader immunology indications," the company said, adding that the candidate has the potential for a "best-in-class profile with expected Q8W-Q12W subcutaneous dosing and picomolar affinity for both TL1A monomers and trimers."
The company's pipeline also includes monoclonal antibody SPY003, which targets the p19 subunit of IL-23 engineered with half-life extension technology, and it anticipates filing an IND application in 2025. Spyre highlighted data from the Phase III SEQUENCE study pitting AbbVie's IL-23 inhibitor Skyrizi (risankizumab) against Johnson & Johnson's IL-12 and IL-23 antagonist Stelara (ustekinumab) in Crohn's disease. According to Spyre, the SEQUENCE trial "validates" its approach of targeting the p19 subunit "as it demonstrated superiority to targeting the p40 subunit of IL-23."
Meanwhile, on the management front, along with the appointment of Turtle as CEO, the company has also named Joshua Friedman and Deanna Nguyen to lead clinical development, while MiRa Huyghe will head development operations. In additional, Brian Connolly has been appointed chief technical officer, and Paul Fehlner as chief intellectual property counsel.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.